Results 1 to 10 of about 15,148 (196)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

JTO Clinical and Research Reports, 2020
Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogenic ...
Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD   +1 more
doaj   +3 more sources

RET fusion partners dictate oncogenic potential in undifferentiated spindle cell sarcomas [PDF]

Cancer Biology & Therapy
Background Spindle cell tumors with RET rearrangements exhibit variable clinical behaviors, ranging from benign to highly aggressive malignancies.
Qi Gui, Ying Zhang, Mei Yang, Rongrui Liang, Man Huang, Xiaoshan Yang, Nan Chen, Xiaojun Chen, Mengyao Wu, Huafei Chen, Lijun Meng, Sheng Xiao, Min Tao   +12 more
doaj   +2 more sources

The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis [PDF]

Translational Oncology
Background: RET fusions are significant oncogenic drivers, resulting from chromosomal rearrangements of the RET proto-oncogene with various partner genes.
Yi Zhao, Ruo Du, Mingcong Chen, Zhiwei Chen   +3 more
doaj   +2 more sources

Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer

Heliyon
Background: Rearranged during transfection (RET) gene fusion is a target for non-small cell lung cancer (NSCLC) treatment, and RET inhibitors are approved for advanced NSCLC.
Rui Wan, Weihua Li, Zhijie Wang, Jia Zhong, Lin Lin, Jianchun Duan, Jie Wang   +6 more
doaj   +3 more sources

Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice [PDF]

JTO Clinical and Research Reports
Introduction: This study presents the development and characterization of a novel lung adenocarcinoma cell line with kinesin family member 5B rearranged during transfection (KIF5B-RET) fusion, derived from a single patient's pleural effusion.
Akihiro Nishiyama, MD, PhD, Shigeki Sato, PhD, Hiroyuki Sakaguchi, PhD, Hiroshi Kotani, PhD, Kaname Yamashita, PhD, Koushiro Ohtsubo, PhD, Shigeki Nanjo, PhD, Seiji Yano, PhD, Keishi Mizuguchi, PhD, Hiroko Ikeda, PhD, Makiko Yamaguchi, MD, Tamotsu Ishizuka, PhD, Satoko Baba, BSc, MT, Kengo Takeuchi, PhD, Shinji Takeuchi, PhD   +14 more
doaj   +2 more sources

Durable Response to Selpercatinib in Metastatic Colorectal Cancer Harboring a Novel TIMM23B::RET Fusion: A Case Report [PDF]

Current Oncology
RET fusions are rare but actionable oncogenic drivers in metastatic colorectal cancer (mCRC), occurring in a small molecular subset with limited clinical evidence for selective RET inhibition.
Ziyan Tong, Mengyuan Yang, Shanshan Weng, Ying Yuan   +3 more
doaj   +2 more sources

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case

Frontiers in Oncology
BackgroundRearranged during transfection (RET) fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential.
Raffaella Pagliaro, Raffaella Pagliaro, Paola Maria Medusa, Paola Maria Medusa, Fabiana Vitiello, Luigi Aronne, Luigi Aronne, Susan F. M. Campbell, Susan F. M. Campbell, Fabio Perrotta, Fabio Perrotta, Andrea Bianco, Andrea Bianco   +12 more
doaj   +3 more sources

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

Frontiers in Oncology, 2023
Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously ...
Tongyi Zhang, Hongwei Wang, Zhiwei Cai, Siqi Zhang, Chongyi Jiang, Chongyi Jiang   +5 more
doaj   +1 more source

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer

BMC Cancer, 2023
Background Thyroid cancer is the most frequent malignancy of the endocrine system, of which papillary thyroid cancer (PTC) is the predominant form with a rapid increasing incidence worldwide.
Mengke Chen, Junyu Xue, Ye Sang, Wenting Jiang, Weiman He, Shubin Hong, Weiming Lv, Haipeng Xiao, Rengyun Liu   +8 more
doaj   +1 more source

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset

Translational Oncology, 2023
Background: RET fusions are driver alterations in cancer and are most commonly found in non-small cell lung cancer and well-differentiated thyroid cancer. However, RET fusion have been reported in other solid tumors. Material and methods: A retrospective
Misako Nagasaka, Danielle Brazel, Yasmine Baca, Joanne Xiu, Mohammed Najeeb Al-Hallak, Chul Kim, Jorge Nieva, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Mark A. Socinski, Luis E. Raez, Balazs Halmos, Sai-Hong Ignatius Ou   +13 more
doaj   +1 more source